Conavi files prospectus for share offering

Executive Summary

• Conavi Medical Corp. has filed a preliminary short form prospectus for a proposed public offering of common shares and/or pre-funded common share purchase warrants.
• The offering is being managed by Bloom Burton Securities Inc. on an agency basis, with final pricing and size to be determined at the time of pricing.
• Net proceeds are intended to secure US FDA 510(k) clearance for the next-generation Novasight Hybrid system, fund a limited market release, and initiate a broader commercial launch in the US, alongside working capital needs.

Key Details

• Securities Offered: Common shares of Conavi Medical Corp. and/or pre-funded common share purchase warrants (in lieu of common shares).
• Agent: Bloom Burton Securities Inc.
• Offering Basis: Commercially reasonable efforts agency basis.
• Pricing and Size: To be determined by negotiation between the company and Bloom Burton Securities based on market conditions; final terms to be set at pricing.
• Use of Proceeds:
  • Obtain United States FDA 510(k) clearance for the next generation Novasight Hybrid system.
  • Complete a limited market release and initiate a broader commercial launch in the United States.
  • Working capital and other general corporate purposes.
• Expected Closing Date: On or about December 12, 2025, or such later date as agreed upon by the company and Bloom Burton.
• Conditions: Subject to entering into a definitive agency agreement and satisfaction of customary closing conditions, including regulatory and stock exchange approvals (specifically TSX Venture Exchange).
• Jurisdiction: Securities anticipated to be offered via private placement in certain jurisdictions outside of Canada in compliance with applicable securities laws.
• Regulatory Filing: Preliminary short form prospectus filed with securities regulatory authorities in British Columbia, Alberta, and Ontario.

Notable Quotes

• No direct quotes from management were included in the provided text.